Salarius Pharmaceuticals, Inc.
SLRX
$0.8773
-$0.0186-2.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.50% | 44.22% | -41.89% | -22.62% | -9.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.99% | 53.36% | -60.25% | -63.05% | -67.32% |
| Operating Income | 2.99% | -53.36% | 60.25% | 63.05% | 67.32% |
| Income Before Tax | 0.34% | -66.01% | 60.21% | 63.26% | 67.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.34% | -66.01% | 60.21% | 63.26% | 67.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.34% | -66.01% | 60.21% | 63.26% | 67.88% |
| EBIT | 2.99% | -53.36% | 60.25% | 63.05% | 67.32% |
| EBITDA | 2.99% | -53.42% | 60.21% | 63.06% | 67.33% |
| EPS Basic | 68.59% | 43.32% | 85.43% | 79.28% | 81.69% |
| Normalized Basic EPS | 68.60% | 43.32% | 85.43% | 79.28% | 81.69% |
| EPS Diluted | 68.59% | 43.32% | 85.43% | 79.28% | 81.69% |
| Normalized Diluted EPS | 68.60% | 43.32% | 85.43% | 79.28% | 81.69% |
| Average Basic Shares Outstanding | 217.36% | 192.92% | 173.15% | 77.32% | 75.35% |
| Average Diluted Shares Outstanding | 217.36% | 192.92% | 173.15% | 77.32% | 75.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |